Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nomura Report Recommends Otsuka HD, DSP, Eisai Shares
February 10, 2012
- Mr Takeuchi of Astellas Stresses Importance of IP Strategies in Tie-ups with Bioventures
February 10, 2012
- Teijin Aims for ¥400 Billion in Sales in Healthcare by FY2020
February 9, 2012
- Sales of Ethical Drugs Up 5.3% in December: Crecon Report
February 9, 2012
- Meiji Seika Pharma Begins PII Trial of Schizophrenia Drug Ziprasidone in Japan
February 9, 2012
- Santen Pharmaceutical Apr-Dec Sales Up 5.3% on Steady Growth in Japan and Abroad
February 8, 2012
- Novartis President Mitani Says Diovan Patent Expiry an “Urgent Issue”
February 8, 2012
- Novartis Domestic Sales Up 6% Despite Drop in Diovan
February 8, 2012
- All-Case PMS for Chugai’s Tarceva for NSCLC Lifted
February 8, 2012
- Janssen Files NDA for Anti-HIV Agent Edurant in Japan
February 8, 2012
- JCR Hopes to Build Delivery Network, Boost Product Promotion in Collaboration with Medipal: Chairman Ashida
February 7, 2012
- DSP President Tada Says Steady Shift to Latuda Seen in US
February 7, 2012
- JCR to Push Joint Development with GSK, Including New Biopharmaceuticals
February 7, 2012
- Apr-Dec Sales Rise 7.4% due to Vidaza: Nippon Shinyaku
February 7, 2012
- Apr-Dec Sales Up 1.9% Driven by Artz: Kaken
February 7, 2012
- Astellas to Establish New Global Human Resources Committee on April 1
February 7, 2012
- Takeda Announces US Launch of Combination Hypertension Treatment Edarbyclor
February 7, 2012
- Sanofi-aventis Initiates ALOHA 2 Study of Lantus Plus DPP-4 Inhibitors for Type 2 Diabetes
February 7, 2012
- Pfizer Japan to Launch 2 Generic APIs on Feb 8, Total 18 APIs
February 6, 2012
- OncoTherapy to Jointly Initiate PIII Study for OCV-C01 with Otsuka
February 6, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…